Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
24 April 2023 | Story Gerda-Marié van Rooyen | Photo Charl Devenish
Jenna Clarkson
Jenna Clarkson is a devout communications student and a karateka. She had to deal with several health challenges during her studies, but nevertheless dreams of obtaining her PhD in Communication at the UFS.

Overcoming numerous health obstacles during her studies, Jenna Clarkson is in high spirits after obtaining her degree from the University of the Free State (UFS). While most students enjoyed an active social and campus life, she often had to visit the hospital while studying. Receiving her BA Integrated Organisational Communication qualification during the April 2023 graduation ceremony has been a healing balm after many years of pain. 
 
The Faculty of the Humanities graduate was diagnosed with type 2 diabetes in 2021. In 2022, after several physiotherapists and emergency room visits, she was also diagnosed with juvenile disc disorder and sacroiliitis. The latter condition affects one or both sacroiliac joints where the lower spine and pelvis meet and may cause pain in one or both legs. 

Initially, Jenna assumed she had hurt herself during karate practice, but the pain would not subside. “I would randomly lose feeling in my legs and couldn’t sit. I spent a year in pain and struggled to walk, lift heavy objects, cough, and sleep on my side. I struggled with the fact that this was going to be an issue for the rest of my life.” 

However, with a lot of love from her friends, support from her lecturers, and grace with herself, Jenna learned how to handle the pain and to realise when she has met her limits. This student from Johannesburg says that although pain is frustrating and overwhelming, having emotional support helps. “Sometimes just having someone to listen and be there is the best thing.”

The journey to the graduation stage might have been difficult for this high-flyer, but it was a worthwhile undertaking. 

“I feel over the moon, and a little overwhelmed that it happened,” says Jenna about getting her degree in communications. Loving her field of study, she attended class eagerly and enjoyed her modules. “I love that I am allowed to create, I get to make something. There’s nothing more amazing than getting a brief and being able to look at it and create something from it that nobody else would have created. The bonus is that I am quite good at it too,” adds the student who is currently doing her honours degree at the UFS. 

Getting her first degree from the UFS, Jenna is determined to excel in her chosen field. 

“I would like to get my honours degree cum laude and do a PhD degree, but I am taking it one degree at a time. If it doesn’t work out that way, it’s okay. I am very good at figuring things out and making a plan.”

Jenna is determined to make her parents proud. “Having lost my dad at four, I do everything with the hope that he would be proud of my choices. My mom sacrificed a lot to give me the best life she could.”

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept